We innovate with a focus on three therapeutic areas - oncology, gastroenterology (GI), and the central nervous system (CNS). We also leverage world-class capabilities to develop vaccines to address critical public health threats using novel development platforms and collaborate with leading partners.
CNS disorders are complex multifaceted conditions that affect the spectrum of mental health. We are driven to provide novel therapies for people with psychiatric, neurological and rare central nervous system disorders (CNS) disorders who lack adequate treatment options.
For more than 25 years, Takeda has focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs in gastroenterology (GI). Takeda is leading in areas of GI associated with high unmet need, such as inflammatory bowel disease, GI acid-related diseases and GI motility disorders.
We endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies.
Please visit takedaoncology.com for more information.
Vaccines have transformed global public health. Our world-class vaccine team is addressing unmet medical needs through vaccine development against infectious diseases, while using innovative development platforms and collaborating with leading partners.
Date of Preparation : December 2017